The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Published Online:https://doi.org/10.1176/foc.1.1.15

There is growing evidence that bipolar disorder and bipolar spectrum disorders are both prevalent and pernicious. They may cause profound impairment in all aspects of a patient’s life and frequently disrupt the structure of the patient’s entire social network. Beyond a consensus that most patients with bipolar disorder will require continuous treatment, relatively little is known about the long-term management of either bipolar I or bipolar II disorder. Although managing depression and depressive symptoms is the greatest challenge faced by patients with these disorders and the physicians who treat them, prevention of mania, rather than depression, has been the focus of most research efforts. This review article will summarize research evidence regarding the utility of lithium, anticonvulsant agents, antipsychotic medications, antidepressant medications, and electroconvulsive therapy in preventing relapse of depressive symptoms for patients with bipolar I and bipolar II disorders.